Shots:

• The P-I study involved assessing of [Fam-] trastuzumab deruxtecan (5.4- 6.4 mg/kg) in 46 patients with heavily pretreated HER2 low expressing metastatic breast cancer
• P-I study results: ORR (44.2 %- 47.4%); disease control rate (79.1%- 81.6%); mDOR (9.4mos.- 11.0 mos.); mPFS (7.6 mos.- 7.9 mos.)
• [Fam-] Trastuzumab deruxtecan (DS-8201) is a HER2 targeting antibody drug conjugate (ADC) targeted for delivering CT in cancer cells and is evaluated in P-III for HER2 positive metastatic breast cancer

Ref: Daiichi Sankyo | Image: Specialty Pharma Journal